skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma

Abstract

Purpose: Nasopharyngeal carcinoma (NPC) has been proven as an Epstein-Barr virus (EBV)-associated cancer. Serum anti-EBV antibodies and plasma EBV DNA have been investigated as surrogate markers for NPC. A comparison of the prognostic impacts of both assays has never been reported. Methods and Materials: Paired serum and plasma samples from 114 previously untreated NPC patients were collected and subjected to an immunofluorescence assay for immunoglobulin (Ig)A and IgG antibodies against the viral capsid antigen (VCA) and a real-time quantitative polymerase chain reaction assay for EBV DNA measurement. The effects of both assays on patient prognosis were thoroughly investigated. Results: Relapsed patients had significantly higher pretreatment EBV DNA concentration than patients without relapse (p 0.0006). No associations of VCA-IgA (p = 0.9669) or VCA-IgG (p = 0.6125) were observed between patients with and without relapse. The 4-year overall survival (60.3% vs. 93.1%, p < 0.0001) and relapse-free survival rates (54.4% vs. 77.9%, p = 0.0009) were significantly lower in patients with higher pretreatment EBV DNA load than in those with lower EBV DNA load. Patients with persistently detectable EBV DNA after treatment had significantly worse 4-year overall (30.8% vs. 84.6%, p < 0.0001) and relapse-free survival rates (15.4% vs. 74.0%, pmore » < 0.0001) than those with undetectable EBV DNA. The VCA-IgA and VCA-IgG titer could not predict survivals (all p > 0.1). Cox multivariate analyses also showed the same results. Conclusion: Plasma EBV DNA is superior to serum EBV VCA antibodies in prognostic predictions for NPC.« less

Authors:
 [1];  [2];  [3];  [4];  [5];  [6];  [5];  [7];  [8]
  1. Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan (China)
  2. (China)
  3. Section of Basic Medicine, Department of Nursing, Hung Kuang University, Taichung (China)
  4. Department of Public Health, China Medical University, Taichung (China)
  5. Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung (China)
  6. Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung (China)
  7. Department of Pathology, National Cheng Kung University Hospital, Tainan (China)
  8. Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan (China) and Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung (China) and Department of Medicine, School of Medicine, China Medical University, Taichung, Taiwan (China). E-mail: jclin@vghtc.gov.tw
Publication Date:
OSTI Identifier:
20850305
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 67; Journal Issue: 1; Other Information: DOI: 10.1016/j.ijrobp.2006.07.012; PII: S0360-3016(06)01172-2; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANTIBODIES; ANTIGENS; CARCINOMAS; DNA; IMMUNOGLOBULINS; MULTIVARIATE ANALYSIS; ONCOGENIC VIRUSES; PATIENTS; POLYMERASE CHAIN REACTION

Citation Formats

Twu, C.-W., Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung, Wang, W.-Y., Liang, W.-M., Jan, J.-S., Jiang, R.-S., Chao, Jeffrey, Jin, Y.-T., and Lin, J.-C. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. United States: N. p., 2007. Web. doi:10.1016/j.ijrobp.2006.07.012.
Twu, C.-W., Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung, Wang, W.-Y., Liang, W.-M., Jan, J.-S., Jiang, R.-S., Chao, Jeffrey, Jin, Y.-T., & Lin, J.-C. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. United States. doi:10.1016/j.ijrobp.2006.07.012.
Twu, C.-W., Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung, Wang, W.-Y., Liang, W.-M., Jan, J.-S., Jiang, R.-S., Chao, Jeffrey, Jin, Y.-T., and Lin, J.-C. Mon . "Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma". United States. doi:10.1016/j.ijrobp.2006.07.012.
@article{osti_20850305,
title = {Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma},
author = {Twu, C.-W. and Department of Otorhinolaryngology, Taichung Veterans General Hospital, Taichung and Wang, W.-Y. and Liang, W.-M. and Jan, J.-S. and Jiang, R.-S. and Chao, Jeffrey and Jin, Y.-T. and Lin, J.-C.},
abstractNote = {Purpose: Nasopharyngeal carcinoma (NPC) has been proven as an Epstein-Barr virus (EBV)-associated cancer. Serum anti-EBV antibodies and plasma EBV DNA have been investigated as surrogate markers for NPC. A comparison of the prognostic impacts of both assays has never been reported. Methods and Materials: Paired serum and plasma samples from 114 previously untreated NPC patients were collected and subjected to an immunofluorescence assay for immunoglobulin (Ig)A and IgG antibodies against the viral capsid antigen (VCA) and a real-time quantitative polymerase chain reaction assay for EBV DNA measurement. The effects of both assays on patient prognosis were thoroughly investigated. Results: Relapsed patients had significantly higher pretreatment EBV DNA concentration than patients without relapse (p 0.0006). No associations of VCA-IgA (p = 0.9669) or VCA-IgG (p = 0.6125) were observed between patients with and without relapse. The 4-year overall survival (60.3% vs. 93.1%, p < 0.0001) and relapse-free survival rates (54.4% vs. 77.9%, p = 0.0009) were significantly lower in patients with higher pretreatment EBV DNA load than in those with lower EBV DNA load. Patients with persistently detectable EBV DNA after treatment had significantly worse 4-year overall (30.8% vs. 84.6%, p < 0.0001) and relapse-free survival rates (15.4% vs. 74.0%, p < 0.0001) than those with undetectable EBV DNA. The VCA-IgA and VCA-IgG titer could not predict survivals (all p > 0.1). Cox multivariate analyses also showed the same results. Conclusion: Plasma EBV DNA is superior to serum EBV VCA antibodies in prognostic predictions for NPC.},
doi = {10.1016/j.ijrobp.2006.07.012},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 1,
volume = 67,
place = {United States},
year = {Mon Jan 01 00:00:00 EST 2007},
month = {Mon Jan 01 00:00:00 EST 2007}
}